Core Points - GT Medical Technologies, Inc. has secured a 15 million has been provided by Horizon Technology Finance Corporation, which will enable the company to enhance access to care for patients with brain tumors [1][2][4] - GammaTile® is a targeted radiation therapy solution designed to reduce tumor recurrence by delivering radiation directly to the tumor cavity, minimizing damage to healthy tissue [4][6] Company Overview - GT Medical Technologies aims to improve the lives of patients with brain tumors and has developed GammaTile®, which is FDA-cleared for treating newly diagnosed and recurrent malignant intracranial neoplasms [6] - Since its market release in March 2020, GammaTile has been adopted by over 100 leading institutions, with ongoing expansion [6] Financial Partnership - The partnership with Horizon Technology Finance Corporation is expected to allow GT Medical Technologies to invest more resources into GammaTile and expand its commercial teams to reach more patients [6][4] - Horizon Technology Finance specializes in providing capital to venture-backed companies in various sectors, including healthcare [7]
GT Medical Technologies, Inc. Secures $35 Million Venture Loan Facility from Horizon Technology Finance